research Miscellaneous Exogenous Hormones and Breast Diseases: A Matter of Concern for the Gynecologist
Some hormone treatments might raise breast cancer risk, while others don't seem to.
Search
for
Sort by
Research
300-330 / 1000+ results research Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
The cream effectively and safely reduces facial hair in women.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Anabolic potential of bone mineral in human periosteal fibroblasts using steroid markers of healing
Bone mineral and minocycline boost bone cell growth, aiding healing.
research Steroid 5α-Reductase Inhibitors
New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
research Pharmacokinetics and Bioconversion of Dehydroepiandrosterone after Application of Dexamethasone in Women with Polycystic Ovary Syndrome
Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
research Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
research Androgen Therapy for Postmenopausal Women; What is New?
research A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs).
Both vaginal testosterone cream and Estring effectively manage vaginal dryness in women with early-stage breast cancer on aromatase inhibitors.
research Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research 440 Topical application of anti-cancer drug Bortezomib stimulates proliferation of follicular cells and induces expression of hair keratins via GATA-3 transcription factor
Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
research The Safety of Testosterone Therapy in Women
Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
research 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예
Bortezomib chemotherapy can cause temporary skin rashes.
research A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism
All treatments reduce hair growth; low dose flutamide most effective with fewer side effects.
research Polyamine Oxidase Expression Is Downregulated by 17β-Estradiol via Estrogen Receptor 2 in Human MCF-7 Breast Cancer Cells
17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.
research Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism
The treatment temporarily improved symptoms of hyperandrogenism in adolescents.
research A Comparative Study of Diane‐35 plus Spironolactone and Diane ‐35 Plus Finasteride in Cases of Hirsutism and Acne
Both Diane 35 combinations effectively and safely reduce hirsutism and acne, with potential for better results if treatment extends beyond 12 months.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research New Drugs: Dutasteride
Dutasteride is approved to help manage prostate enlargement.
research MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen1
MK-386 lowers DHT in blood and skin but not in semen.
research New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors
New compounds may help treat prostate issues without affecting androgen receptors.
research FINASTERIDE (PLUS ORAL CONTRACEPTIVE PILL) VS METFORMIN IN TREATMENT OF POLYCYSTIC OVARY SYNDROME-RELATED INFERTILITY: A PROSPECTIVE RANDOMIZED TRIAL
research The Antiandrogens
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
research Synthesis of avicequinone c and analogs toward the study of 5α-reductase inhibitory activity
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
research Faculty Opinions recommendation of Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss.
Flutamide, an oral anti-androgen therapy, is effective in treating female pattern hair loss, even without systemic androgen excess.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.